Publications by authors named "R E Kates"
Background: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of this study was to evaluate the association between TNBC-DX and efficacy outcomes [pathologic complete response (pCR), distant disease-free survival (DDFS) or event-free survival (EFS), and overall survival (OS)] in the validation cohorts.
View Article and Find Full Text PDFArticle Synopsis
- Breast cancer patients often face significant side effects from treatment, including reduced muscle strength and quality of life, but exercise, particularly resistance training, has shown positive outcomes.
- A study involved 40 patients undergoing chemotherapy, with half participating in a high-intensity resistance training program while the other half received standard care.
- Results indicated that those who engaged in the resistance training saw significant improvements in strength and quality of life, suggesting that tailored exercise programs should be further explored in future research.
Background: Oral cancer medications offer advantages but also pose challenges for therapy management and adherence. An eHealth-based platform such as CANKADO can help to support therapy management by probing the patient's quality of life (QoL) continuously throughout the course of treatment.
Material And Methods: AGO-B WSG PreCycle (NCT03220178) is a multicenter, randomized phase IV intergroup trial evaluating the impact of eHealth-based Patient-Reported Outcome (ePRO) assessment on QoL in patients with hormone receptor-positive (HR + )/HER2-negative (HER2-) advanced breast cancer treated with palbociclib and endocrine therapy.
Background: The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality of life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor or palbociclib + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is an interactive autonomous application reacting to patient self-reported observations.
Patients And Methods: Between 2017 and 2021, 499 patients (median age 59 years) from 71 centers were randomized (2 : 1, stratified by therapy line) between an active version of CANKADO PRO-React (CANKADO-active arm) and a version with limited functionality (CANKADO-inform arm).
Article Synopsis
- Researchers are studying how to help people with a type of breast cancer (HR+ HER2-) stick to their treatment, especially when taking new oral medications like palbociclib.
- They are conducting a trial called PreCycle with 960 patients to see how different eHealth systems (CANKADO active vs. CANKADO inform) can improve the quality of life and keep track of medicine intake.
- The study also looks at how personal factors (like genes) and behavior might affect how well the treatment works for each patient.